The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...

In an accompanying abstract, we offer evidence that maternally administered digoxin does not readily cross the placenta of fetuses with cardiac disease. We have now administered digoxin and digitoxin ...

MADRID, Spain—Adding digitoxin, a cardiac glycoside, to contemporary guideline-directed medical therapy (GDMT) improves clinical outcomes in patients who have heart failure with reduced ejection ...

Cardiac glycosides derived from the foxglove plant have been used in cardiology for two centuries, but digoxin and digitoxin have gradually fallen out of favor and are now considered controversial in ...

MADRID -- Digitoxin added to guideline-directed medical therapy improved outcomes among patients with heart failure and reduced ejection fraction (HFrEF), the DIGIT-HF trial showed. The cardiac ...

Digitoxin reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and a reduced ejection fraction (HFrEF), according to ...

Please provide your email address to receive an email when new articles are posted on . Digitoxin reduced risk for death or worsening heart failure vs. placebo in patients with heart failure with ...

New findings from the DIGIT-HF trial show low-dose digitoxin can reduce the risk for hospitalization and all-cause mortality in patients with symptomatic heart failure. The results, presented at the ...

Madrid, Spain – 29 August 2025: Digitoxin reduced the risk of a composite of all-cause death and hospitalisation for worsening heart failure (HF) among patients with advanced HF and a reduced ejection ...